scholarly journals A Survey of Intensive Care Units: First Line Drug Therapy for Delirium

2012 ◽  
Vol 13 (2) ◽  
pp. 173-174
Author(s):  
R. Malhotra
Keyword(s):  
Intensive Care ◽  
Drug Therapy ◽  
Intensive Care Units ◽  
First Line ◽  
Line Drug

Agitation and Delirium

2018 ◽  
Author(s):  
Eelco F. M. Wijdicks ◽  
Sarah L. Clark
Keyword(s):  
Intensive Care ◽  
Intensive Care Units ◽  
Nursing Staff ◽  
Atypical Antipsychotics ◽  
Line Treatment ◽  
Bodily Harm ◽  
First Line ◽  
First Line Treatment

Delirium involves abnormalities in perception and in attention with failure of the caregiver to correct or recognize behavior. Marked agitation disturbs the patient’s orientation, attention, and sleep. The effects of uncontrolled agitation are manifold and not in the least causing bodily harm. In intensive care units, agitation and delirium occur in the sickest patients. Treatment of delirium is necessary and needed early after recognition. In this chapter, the best pharmacologic approaches and indications are discussed, including neuroleptics. Atypical antipsychotics are the first-line treatment for delirium. Recognition of delirium starts with the nursing staff and the identification of medications that are associated with triggering delirium.

An overview of some drugs: Lopinavir, Ritonavir, Chloroquine, Hydroxy chloroquine and Interferon as a effective treatment against COVID-19

2020 ◽  
Vol 10 (1) ◽  
pp. 20-24
Author(s):  
Sujaritha J ◽  
Deepa sankar N ◽  
Mathivathani K ◽  
Aravindh G ◽  
Gnanasekaran G
Keyword(s):  
Rheumatoid Arthritis ◽  
Plasmodium Falciparum ◽  
Drug Therapy ◽  
Hiv Infection ◽  
Effective Treatment ◽  
Protease Inhibitors ◽  
First Line ◽  
Duration Of Illness ◽  
Line Drug

Lopinavir, Ritonovir and Interferon (IFN) are anti-viral drugs mainly used in the treatment of HIV infection by protease inhibitors. Chloroquine and Hydroxychloroquine are used in the treatment of malarial causing infection such as Plasmodium falciparum and also auto immune condition such as rheumatoid arthritis. Chloroquine makes toxic for the parasite to digest its host hemoglobin and disrupting the virus ability to enter the cell. The anti-viral and anti-malarial drugs are used in the first line drug therapy for the treatment of COVID-19. The aim of this therapy is to minimize the symptoms and shortens the duration of illness.

Clinical Outcomes of Three or More Courses of First-line Chemotherapy for Metastatic Urothelial Carcinoma

2021 ◽  
Vol 1 (5) ◽  
pp. 459-461
Author(s):  
SHOHEI KAWAGUCHI ◽  
KOUJI IZUMI ◽  
RENATO NAITO ◽  
SUGURU KADOMOTO ◽  
HIROAKI IWAMOTO ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Urothelial Carcinoma ◽  
Focal Therapy ◽  
Line Treatment ◽  
Second Line ◽  
First Line ◽  
Metastatic Urothelial Carcinoma ◽  
Line Drug ◽  
Line Chemotherapy ◽  
First Line Treatment

Background/Aim: The current standard of care for first-line treatment of locally advanced or metastatic urothelial carcinoma (UC) is platinum-based combination chemotherapy. Recently, immune checkpoint inhibitors have been reported to be effective for UC. Knowing whether immunotherapy or chemotherapy is suitable as first-line treatment is beneficial for patients. A retrospective study was conducted on the clinical outcomes of Japanese patients who received three or more courses of first-line chemotherapy for metastatic UC to assess the outcome of conventional treatments in real clinical situation. Patients and Methods: Patients who received first-line chemotherapy between August 2009 and December 2019 were included. Progression-free survival (PFS) and overall survival (OS) were assessed. Results: The median PFS and OS were 7.1 and 27.1 months, respectively, for patients with no disease progression at the end of three courses. Of 28 patients, 25 (89.3%) received second-line drug therapy and 10 (35.7%) received focal therapy for disease control. Patients with focal therapy had significantly longer OS than those without focal therapy (p=0.019, log-rank test). Conclusion: OS of metastatic UC at our Institution is relatively long, suggesting that aggressive second-line drug therapy and focal therapy may have contributed to such result.

A data model for managing drug therapy within a patient data management system for intensive care units

2003 ◽  
Vol 70 (1) ◽  
pp. 71-79 ◽  
Author(s):  
Achim Michel ◽  
Axel Junger ◽  
Matthias Benson ◽  
Dominik G. Brammen ◽  
Gunter Hempelmann ◽  
...  
Keyword(s):  
Intensive Care ◽  
Drug Therapy ◽  
Data Management ◽  
Intensive Care Units ◽  
Data Model ◽  
Management System ◽  
Patient Data ◽  
Patient Data Management System ◽  
Data Management System

scholarly journals Desmopressin 120 mcg, 180 mcg, 240 mcg: The right treatment for the right patient

2018 ◽  
Vol 90 (2) ◽  
pp. 127 ◽  
Author(s):  
Pietro Ferrara ◽  
Ester Del Vescovo ◽  
Francesca Ianniello ◽  
Giulia Franceschini ◽  
Luciana Romaniello ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Nocturnal Enuresis ◽  
Bladder Function ◽  
Efficacy And Safety ◽  
Nocturnal Polyuria ◽  
First Line ◽  
Normal Bladder ◽  
Increased Risk ◽  
The Right ◽  
Line Drug

Background: The first-line drug therapy for patients with nocturnal enuresis (NE) associated with nocturnal polyuria and normal bladder function is desmopressin (dDAVP). Objective: To evaluate if increasing dose of oral desmopressin lyophilisate (MELT) can improve response rates to dDAVP and is useful in enuretic children. Materials and methods: We enrolled a total of 260 children all diagnosed with NE. Enuretic children were treated with increasing MELT at a dose of 120, 180 and 240 mcg a day.Results. We included in our study a total of 237 children, 164 males (69.2%) and 73 females (30.8%) aged between 5 and 18 years (mean age 10.32 ± 2.52 years). Of the 237 patients enrolled in the study and treated with MELT 120 mcg, a full response was achieved in 135 (56.9%). A partial response was achieved in 21 (8.9%) patients, therefore the dose was increased up to 180 mcg, with further improving symptoms (14.3%) or full response (9.5%), and up to 240 mcg, without usefulness. Conclusions: MELT at the dose of 120 mcg resulted efficacy and safety; the increased dose up to 180 mcg resulted poorly efficacy; finally, the further increase up to 240 mcg did not improve the symptoms with the increased risk of side effects.

Anaphylaxis Knowledge Among Pediatric Intensivists in Brazil: A Multicenter Survey

2016 ◽  
Vol 32 (10) ◽  
pp. 593-596 ◽  
Author(s):  
José Colleti Junior ◽  
Werther Brunow de Carvalho
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Pediatric Intensive Care ◽  
World Allergy Organization ◽  
First Line ◽  
Cross Sectional ◽  
Multicenter Survey ◽  
Knowledge And Practice ◽  
Line Drug ◽  
Question Survey

Objective: To assess the knowledge and practice preferences of anaphylaxis treatment among pediatric intensivists in 5 Brazilian pediatric intensive care unit (PICU) settings. Study Design: The cohort was a cross-sectional sample from 5 PICUs; a 7-question survey was personally applied to participants regarding their professional clinical experience and the first-line drug choices when treating an anaphylaxis episode. Results: Of 43 participant physicians, the majority (83.8%) correctly identified epinephrine as the treatment of choice for anaphylaxis, yet only 41.9% chooses the intramuscular route of administration. Conclusion: This study shows that the knowledge of anaphylaxis treatment is deficient among pediatric intensivists in Brazil. The dissemination of recent World Allergy Organization guidelines on anaphylaxis should be encouraged.

Sign in / Sign up

Export Citation Format

Share Document